These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18084956)

  • 1. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.
    Schlingensiepen KH; Fischer-Blass B; Schmaus S; Ludwig S
    Recent Results Cancer Res; 2008; 177():137-50. PubMed ID: 18084956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.
    Schlingensiepen KH; Schlingensiepen R; Steinbrecher A; Hau P; Bogdahn U; Fischer-Blass B; Jachimczak P
    Cytokine Growth Factor Rev; 2006; 17(1-2):129-39. PubMed ID: 16377233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2.
    Jaschinski F; Rothhammer T; Jachimczak P; Seitz C; Schneider A; Schlingensiepen KH
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2203-13. PubMed ID: 21619536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
    Hau P; Jachimczak P; Bogdahn U
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.
    Hau P; Jachimczak P; Schlingensiepen R; Schulmeyer F; Jauch T; Steinbrecher A; Brawanski A; Proescholdt M; Schlaier J; Buchroithner J; Pichler J; Wurm G; Mehdorn M; Strege R; Schuierer G; Villarrubia V; Fellner F; Jansen O; Straube T; Nohria V; Goldbrunner M; Kunst M; Schmaus S; Stauder G; Bogdahn U; Schlingensiepen KH
    Oligonucleotides; 2007; 17(2):201-12. PubMed ID: 17638524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β2 signaling in high-grade gliomas.
    Hau P; Jachimczak P; Schlaier J; Bogdahn U
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2150-7. PubMed ID: 21619538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.
    Schlingensiepen KH; Jaschinski F; Lang SA; Moser C; Geissler EK; Schlitt HJ; Kielmanowicz M; Schneider A
    Cancer Sci; 2011 Jun; 102(6):1193-200. PubMed ID: 21366804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.
    Vallières L
    IDrugs; 2009 Jul; 12(7):445-53. PubMed ID: 19579166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.
    Bogdahn U; Hau P; Stockhammer G; Venkataramana NK; Mahapatra AK; Suri A; Balasubramaniam A; Nair S; Oliushine V; Parfenov V; Poverennova I; Zaaroor M; Jachimczak P; Ludwig S; Schmaus S; Heinrichs H; Schlingensiepen KH;
    Neuro Oncol; 2011 Jan; 13(1):132-42. PubMed ID: 20980335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma.
    Fakhrai H; Mantil JC; Liu L; Nicholson GL; Murphy-Satter CS; Ruppert J; Shawler DL
    Cancer Gene Ther; 2006 Dec; 13(12):1052-60. PubMed ID: 16826191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.
    Huber-Ruano I; Raventós C; Cuartas I; Sánchez-Jaro C; Arias A; Parra JL; Wosikowski K; Janicot M; Seoane J
    Ann Oncol; 2017 Sep; 28(9):2278-2285. PubMed ID: 28911087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
    Nickl-Jockschat T; Arslan F; Doerfelt A; Bogdahn U; Bosserhoff A; Hau P
    Int J Oncol; 2007 Feb; 30(2):499-507. PubMed ID: 17203233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.
    Liu Y; Wang Q; Kleinschmidt-DeMasters BK; Franzusoff A; Ng KY; Lillehei KO
    J Neurooncol; 2007 Jan; 81(2):149-62. PubMed ID: 16941073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
    Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
    Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of transforming growth factor β2 by anti-sense oligonucleotide improves immunotherapeutic potential of IL-2 against melanoma in a humanized mouse model.
    Lee HK; Shin HJ; Koo J; Kim TH; Kim CW; Go RE; Seong YH; Park JE; Choi KC
    Cytotherapy; 2021 Jul; 23(7):599-607. PubMed ID: 33975794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.
    Marzo AL; Fitzpatrick DR; Robinson BW; Scott B
    Cancer Res; 1997 Aug; 57(15):3200-7. PubMed ID: 9242450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2.
    Arslan F; Bosserhoff AK; Nickl-Jockschat T; Doerfelt A; Bogdahn U; Hau P
    Br J Cancer; 2007 May; 96(10):1560-8. PubMed ID: 17453002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific inhibition of transforming growth factor-beta2 expression in human osteoblast cells by antisense phosphorothioate oligonucleotides.
    Shen ZJ; Kim SK; Kwon OS; Lee YS; Moon BJ
    Eur J Biochem; 2001 Apr; 268(8):2331-7. PubMed ID: 11298751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.